Roeland Nusse - Aug 30, 2023 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Director
Signature
Andrew Nick as Attorney-in-Fact for Roeland Nusse pursuant to Power of Attorney previously filed
Stock symbol
TECH
Transactions as of
Aug 30, 2023
Transactions value $
-$1,159
Form type
4
Date filed
9/1/2023, 04:06 PM
Previous filing
Apr 21, 2023
Next filing
Oct 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $350K +16K +55.53% $21.85 44.8K Aug 30, 2023 Direct
transaction TECH Common Stock Options Exercise $367K +16K +35.71% $22.95 60.8K Aug 30, 2023 Direct
transaction TECH Common Stock Sale -$718K -8.94K -14.7% $80.32 51.9K Aug 30, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -16K -100% $0.00* 0 Aug 30, 2023 Common Stock 16K $21.85 Direct
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -16K -100% $0.00* 0 Aug 30, 2023 Common Stock 16K $22.95 Direct
holding TECH Stock Options (Right to Buy) 17K Aug 30, 2023 Common Stock 17K $21.84 Direct
holding TECH Stock Options (Right to Buy) 15.9K Aug 30, 2023 Common Stock 15.9K $25.30 Direct
holding TECH Stock Options (Right to Buy) 12.5K Aug 30, 2023 Common Stock 12.5K $31.26 Direct
holding TECH Stock Options (Right to Buy) 7.59K Aug 30, 2023 Commo Stock 7.59K $44.96 Direct
holding TECH Stock Options (Right to Buy) 8.04K Aug 30, 2023 Common Stock 8.04K $50.41 Direct
holding TECH Stock Options (Right to Buy) 6.03K Aug 30, 2023 Common Stock 6.03K $63.92 Direct
holding TECH Stock Options (Right to Buy) 2.53K Aug 30, 2023 Common Stock 2.53K $128.81 Direct
holding TECH Stock Options (Right to Buy) 3.46K Aug 30, 2023 Common Stock 3.46K $73.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.09 to $80.78, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The option vests on the earlier of the one year anniversary of the grant date (10/27/2022) or the date of Bio-Techne's 2023 annual meeting of shareholders.